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Abstract  
 
While angiotensin II-infused mice are the most popular model for preclinical aneurysm research 
representative data on incidence, severity and mortality of dissecting abdominal aortic 
aneurysms (AAAs) have never been established, and the influence of confounding factors is 
unknown. In this review, we performed a meta-analysis including 194 manuscripts representing 
1679 saline-infused, 4729 non-treated angiotensin II-infused and 4057 treated angiotensin II-
infused mice. Incidence (60%) and mortality (20%) rates are reported overall as well as for 
grade I (22%), grade II (26%), grade III (29%) and grade IV(24%) aneurysms. Dissecting AAA 
incidence was significantly (p<0.05) influenced by sex, age, genetic background, infusion time 
and dose of angiotensin II. Mortality was influenced by sex, genetic background and dose, but 
not by age or infusion time. Surprisingly, both incidence and mortality were significantly 
different (p<0.05) when comparing angiotensin II-infused mice in descriptive studies (56% 
incidence, 19% mortality) with angiotensin II-infused mice that served as control animals in 
treatment studies designed to either enhance (35% incidence, 13% mortality) or reduce (73% 
incidence, 25% mortality) dissecting AAA formation. After stratification to account for 
confounding factors (selection bias) the observed effect was still present for incidence, but not 
for mortality. Possible underlying causes are detection bias (non-uniform definition for 
detection and quantification of dissecting AAA in mice) or publication bias (studies with 
negative results, related to incidence in the control group, not being published). In conclusion, 
our data indicate that treatment studies using angiotensin II-infused mice should be interpreted 
with caution and provide a new meta-analysis-based reference for incidence and mortality of 
dissecting AAA in this mouse model 
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Introduction 
In clinical practice, abdominal aortic aneurysm (AAA) is defined as a focal dilatation of the 
aortic diameter larger than 1.5 times the original size 1. Due to the asymptomatic nature of the 
disease human data are scarce, especially at an early stage. Therefore animal models of 
aneurysm formation are often used for pre-clinical research 2. The angiotensin II-infused mouse 
model is the most popular mouse model for aneurysm research because it reproduces many 
important features such as macrophage infiltration, medial elastolysis, luminal expansion and 
thrombus formation3-5.  
Since the first paper published by Daugherty et al. in 2000 3, this mouse model has been the 
subject of numerous papers, ranging from the genetic 6-10 over the molecular 2, 11-25 to the 
macroscopic level 26-34. Lesion severity has been reported to vary substantially within this 
mouse model, leading to a subdivision into Grade I-Grade IV aneurysms based on 
morphological characteristics that were visually observed on excised tissue samples 20. Over 
time, a wide range of incidence, severity and mortality rates has been reported for this mouse 
model but reference data are lacking. Moreover, while several confounding factors (sex, age, 
diet) seem to be the same as in human disease, their effect on murine aneurysm pathology has 
never been quantified.   
The angiotensin II mouse model is particularly popular in so-called treatment studies, in which 
the effect of pharmaceutical or genetic interventions on aneurysm incidence, aneurysm severity 
and aneurysm-related mortality are assessed. Since 2001, 143 manuscripts have studied the 
effect of some kind of treatment in angiotensin II-infused mice, often quantifying aneurysm 
presence in terms of the luminal or external diameter change. But despite its ubiquitous use, 
some important differences with human AAAs exist: the latter are located on the infrarenal 
rather than the suprarenal aspect of the abdominal aorta and are characterized by a progressive 
evolution rather than repeated interparietal ruptures 5, 35. In order to avoid confusion, we 
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therefore refer to the angiotensin II-induced lesions as `dissecting AAAs` rather than AAAs 
throughout the current manuscript 36.   
Here, we present a meta-analysis of all manuscripts (up to January 1st, 2015) in which mice 
have been infused with angiotensin II in order to provoke dissecting AAA formation. In first 
instance, our goal was to define reference values for (i) the occurrence of dissecting AAA, (ii) 
the occurrence of different severity levels within animals developing dissecting AAA 
(categorized from grade I-grade IV 20) and (iii) the mortality rate during angiotensin II-infusion, 
related to aneurysm rupture. We also report the influence of different confounding factors such 
as sex, age, diet, genetic background and dose of angiotensin II on incidence and mortality 
rates. The second part of the manuscript focuses on the statistically significant difference that 
was discovered in the incidence and mortality rates of non-treated mice in treatment studies that 
were designed to enhance dissecting AAA, on the one hand, and treatment studies that were 
designed to reduce dissecting AAA, on the other hand. This difference seems to imply that 
many of the reported incidence and mortality rates in literature were biased by the purpose of 
the study. We present a stratified analysis to investigate to what extent this bias could be 
attributed to confounding environmental factors, and to what extent it was related to the 
variability that exists in the criteria used to define AAA presence. Based on these findings, we 
propose alternative criteria to quantify dissecting AAA presence, rather than focusing on 
diameter alone. As such, this manuscripts aims to provide deeper insight into the interpretation 
of angiotensin II-induced dissecting AAA in the past, and provide improved guidelines for its 
interpretation in the future.  
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Methodology 
The meta-analysis included all publications available in Pubmed until January 1st, 2015, using 
the search terms “mice” or “mouse”, “aneurysm” and “angiotensin”. Exclusion criteria were (i) 
the use of different mouse models than angiotensin II infusion (e.g. elastase perfusion or genetic 
modification without angiotensin II infusion), (ii) reporting on locations of aneurysm formation 
different from the abdominal aorta (e.g. intracranial or ascending aneurysms), (iii)  reports 
focused on human aneurysm or aneurysm-related disorders (e.g. Marfan or Loeys-Dietz 
syndrome), (iv) review articles, (v) letters to the editor, (vi) manuscripts that re-used mice from 
a previous manuscript (and had thus already been included in the analysis) and (vii) manuscripts 
for which no access could be obtained. 
From the remaining 194 manuscripts the following data were retrieved from the methods and 
results sections: sex (male/female), diet (normal/high fat), genetic background (ApoE-/- / LdL-/-
/ C57Bl\6 wild type, C57Bl\6 wild type with anti-TGF-β antibodies, C57Bl\6 wild type with 
co-infusion of β-apn), age (ranging from 4 to 72 weeks), angiotensin II infusion dose (ranging 
from 150 to 3000 ng/min/kg), angiotensin II infusion time (ranging from 3 to 84 days), the 
location where dissecting AAA diameters were quantified (lumen diameter or external 
diameter), the threshold of diameter increase used to define dissecting AAA incidence (ranging 
from 110 to 200%) and the reference to which dissecting AAA diameters were compared in 
order to define dissecting AAA (suprarenal diameters in saline-infused control animals, 
baseline suprarenal diameters prior to angiotensin II infusion, diameters of a non-diseased 
segment proximal to the dissecting AAA, diameters of a non-diseased segment distal to the 
dissecting AAA, or lumen diameters at locations where the dissecting AAA was quantified at 
the external diameter). Each study was classified into one of three categories, depending on 
whether its main goal was to describe aneurysm formation, to enhance aneurysm formation, or 
to reduce aneurysm formation in angiotensin II-infused mice. In manuscripts designed to 
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describe murine aneurysm formation, angiotensin II-infused and saline-infused mice were the 
only study groups. In manuscripts designed to enhance or reduce dissecting AAA formation, 
the angiotensin II-infused mice usually functioned as controls to a third group, in which the 
effect of dissecting AAA was reduced or enhanced by pharmacological or genetic treatment. 
Two studies could not be categorized into any of the three categories. For each study the number 
of saline-infused, the number of angiotensin-infused and the number of treated mice was 
retrieved, as well as the reported incidence rate of mice that developed an dissecting AAA and 
mice that died of aneurysm rupture in each category. If the incidence or rupture rates were 
reported in the form of bar plots or percentages an estimate was made based on the available 
data, and if group size was reported as a range the mean value was used. Aneurysm mortality 
was defined as sudden death during the infusion period, since the pathological confirmation of 
an internal bleeding due to aneurysm rupture nor its precise location (hemoabdomen versus 
hemothorax) were mentioned in most manuscripts. Following the most common procedure in 
literature, incidence rates include mortality rates. In several manuscripts a number of different 
treatment groups were reported. If any of the confounding factors were different between 
groups, these were treated as separate studies. If not, incidence rates from different groups were 
added within the same study.  
Statistics 
Odds ratios were calculated for each confounding factor with respect to its reference situation. 
Odds ratios for categorical variables such as sex, diet and genetic background compared 
dissecting AAA incidence or mortality of mice with the less frequently occurring value of the 
confounding factor to the incidence of ‘reference mice’ for that factor (i.e. female was 
compared to male, high fat diet to normal diet, C57Bl\6 to ApoE-/-). Continuous variables such 
as age, angiotensin II dose  and angiotensin II infusion time were first categorized (young: 4-8 
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weeks, old: 25-84 weeks; low dose: 125-749 ng/kg/min, high dose: 1251-3000 ng/kg/min; low 
infusion time: < 7 days) and odds ratios subsequently compared dissecting AAA incidence and 
mortality for these less frequent values to their respective reference situation (adult: 9-24 weeks; 
normal dose: 750-1250 ng/kg/min; normal infusion time: 7-28 days). Reference measurements 
to define dissecting AAA incidence were considered to be external diameters using a threshold 
of a 150% increase in comparison with saline-infused controls. Odds ratios were considered 
significant (p<0.05) if the 95% confidence interval did not include the value OR=1.  
Since we observed an unexpected dependency of both dissecting AAA incidence and mortality 
on the design of the study, we subsequently performed a stratified analysis to find to what extent 
this dependency was related to the presence of confounding factors. First a Fisher’s exact test 
was performed to identify the environmental factors that were correlated with study design on 
both a study level (i.e. quantifying how the number of studies associated to each study design 
was related to each confounding factor) and a mouse level (i.e. quantifying how the 
accumulated aneurysm incidence and mortality for each study design was related to each 
confounding factor). Then a stepwise stratified analysis was performed in which the effect of 
these confounding factors on the odds ratios was investigated at an individual mouse level. For 
each factor, only those mice representing the respective reference situation were withheld (i.e. 
after stratification for age only adult mice were withheld, after stratification for genetic 
background only Apoe-/- mice were withheld, etc.). If any of the confounding factors was not 
reported, or if either the incidence rate or the number of animals were missing, the animals were 
excluded from the stratified analysis. First we corrected the odds ratios for those factors that 
were significantly correlated to study design on both a study and a mouse level. Since a 
significant effect was still visible, stratification was subsequently expanded to confounding 
factors that were only significantly correlated with study design on a mouse level. Finally 
stratification also included measurement related factors.  
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Results 
Metrics of the meta-analysis 
In total 291 papers were analyzed. Forty-two manuscripts were excluded since they studied 
different mouse models, 21 manuscripts focused on human disease, 28 did not report original 
research and 2 manuscripts re-used mice from a previous manuscript, while for 4 manuscripts 
no access could be obtained. Thirty-five manuscripts reported several studies with varying 
incidence rates or confounding factors, each of which was considered as a separate entry for 
the meta-analysis. In total, this approach led to a total number of 252 studies that were extracted 
from 194 manuscripts. An overview can be found in table S1 (supplementary data). These 
manuscripts were published in 64 different journals, with an average journal impact factor of 
5.7 ± 3.7. Overall, the meta-analysis represents 1679 saline-infused, 4729 non-treated 
angiotensin II-infused and 4057 treated angiotensin II-infused mice.  
Dissecting AAA incidence, mortality and grade I-IV morphology 
Overall, 60% of the animals developed a dissecting AAA while the mortality during angiotensin 
II infusion (presumably related to transmural rupture) was found to be 20% (Table 1). In 33 
studies representing 429 dissecting AAAs, aneurysm shapes were categorized into 4 different 
groups, ranging from grade I to grade IV, according to the morphology criterion first described 
by Daugherty et al 20. In angiotensin II-infused mice that did not receive any additional 
treatment, we found an overall incidence of 22% grade I aneurysms, 26% grade II aneurysms, 
29% grade III aneurysms, and 24% grade IV aneurysms. 
The influence of environmental factors on dissecting AAA incidence and mortality 
As reported previously, dissecting AAA incidence was significantly lower for females than for 
males (Table 2, Figure 1). Young mice experienced a significantly lower incidence than adult 
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mice, while old mice showed a significantly higher incidence than adults. Significantly less 
dissecting AAAs were observed in angiotensin II-infused wild-type C57Bl\6 mice than in ApoE 
-/- mice , and also LdL -/- mice had significantly lower incidence than ApoE -/- mice. C57BL\6 
mice that were co-infused with angiotensin II and β-apn had an incidence rate that was not 
different from that of angiotensin II–infused ApoE -/- mice, while C57Bl\6 mice that were 
infused with angiotensin II and injected with anti-TGF-β antibodies had a significantly higher 
incidence than angiotensin II-infused ApoE -/- mice.  
Dissecting AAA incidence was significantly lower for mice receiving a low dose of angiotensin 
II (< 750 ng/kg/min) compared to those receiving a normal dose, but the difference in incidence 
for mice that were infused with higher doses of angiotensin II (> 1250 ng/kg/min) was not 
statistically significant. A high-fat diet did not result in a statistically significant difference in 
incidence compared to normal rodent chow. 
Rupture rate followed the same trend as incidence for nearly all reported confounding factors. 
Mortality during angiotensin II infusion was significantly higher in male mice, anti-TGF-β 
injected mice, and treated mice in studies designed to enhance dissecting AAA. Mortality 
during angiotensin II-infusion was significantly lower in wild type C57Bl\6 mice, LdL -/- mice, 
mice receiving a low dose of angiotensin II, and treated mice in a study designed to reduce 
dissecting AAA. No significant difference in mortality was found in mice co-treated with β-
apn, in mice receiving a high dose of angiotensin II or in mice on a high fat diet. In fact, the 
only confounding factor that had a different influence on mortality than on aneurysm incidence 
was age. While dissecting AAA incidence was significantly lower in young mice than in adult 
mice, no significant difference in mortality could be detected. Similarly, no statistically 
significant difference in mortality was found between old and adult mice.  
The enhancement of reductions and the reduction of enhancements: a short description 
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The most surprising result from our meta-analysis lies in the strong relation that was found 
between study design and  incidence of dissecting AAA in non-treated, angiotensin II-infused 
mice. In manuscripts that were designed to describe murine aneurysm formation the incidence 
rate in angiotensin II-infused mice was 56%. However, in manuscripts that were designed to 
enhance murine aneurysm formation the incidence rate in non-treated, angiotensin II-infused 
mice (that were used as control animals in these studies) was only 35%. Compared to aneurysm-
describing studies, this difference is highly significant and corresponds to an odds ratio of 0.43 
(Table 2, Figure 1). On the other hand, in manuscripts that were designed to reduce murine 
aneurysm formation the incidence rate in non-treated mice (that equally served as control 
animals in these studies) was as high as 73%. Compared to aneurysm-describing studies, this 
difference was highly significant as well, and corresponded to an odds ratio of 2.12 (Table 2, 
Figure 1). When comparing studies designed to enhance dissecting AAA directly to those 
designed to reduce it, the difference in dissecting AAA incidence of non-treated mice was even 
more pronounced (OR=0.20). 
A similar trend could be observed in dissecting AAA mortality rates. In manuscripts that were 
designed to describe murine aneurysm formation the mortality was 19%. However, in 
manuscripts that were designed to enhance murine aneurysm formation the mortality in non-
treated mice was only 13%, while it was 25% in manuscripts that were designed to reduce 
murine aneurysm formation. Both odds ratios were significantly different from 1 (Table 2, 
Figure 1). 
Stratification for environmental factors 
A Fisher’s exact test indicated that study design significantly correlated with sex, genetic 
background, and angiotensin II dose (p<0.05, Table 3). More specifically, researchers tend to 
choose more often male mice and avoid low doses of angiotensin II in studies designed to 
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reduce dissecting AAA (Figure 2). On the other hand researchers conducting studies designed 
to enhance dissecting AAA more often selected LdL -/- or C57Bl/6 mice and used lower doses 
of angiotensin II. In first instance we performed a step-wise stratified analysis in which we 
accounted for the effect of these confounding factors on both incidence and mortality (Table 4, 
Figure 3).  
After stratification for sex, background and dose (the environmental factors significantly 
correlated with study design on both a study level and a mouse level, see Table 3) incidence 
was still significantly lower for studies designed to enhance dissecting AAA. Similarly,  
incidence was still significantly higher for studies designed to reduce it. Further stratification 
for infusion time, age and diet (all of which were only significantly correlated with study design 
on a mouse level) did not influence the odds ratios in either case (Figure 3, top).  Interestingly, 
the difference in mortality rates for studies designed to enhance dissecting AAA disappeared 
after stratification for sex and background. Similarly, the difference in mortality rates for studies 
designed to reduce dissecting AAA disappeared after stratification for sex, background, dose, 
infusion time and diet (Figure 3, bottom).  
The influence of measurement related factors on dissecting AAA incidence and mortality 
We were able to extract the used criterion for aneurysm incidence from 115 out of 194 
manuscripts. In the remaining studies, the exact criterion for dissecting AAA was either not 
mentioned, or we did not manage to locate it within the manuscript. Of the analyzed studies 
only 84% quantified dissecting AAA dimensions, while 16% determined incidence based on 
visual inspection of the tissue. Surprisingly, the different criteria used to define incidence 
criteria result in no less than 31 potential definitions for dissecting AAA incidence (visual 
inspection plus any permutation of 3 diameter thresholds, 5 reference locations and 2 
measurement locations; see Figure 2).   
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Figure 4 shows the odds ratios of those measurement related factors that deviate from the most 
frequently occurring ‘reference’ measurement. Incidence is shown to be significantly lower 
when the threshold to define dissecting AAA presence is put higher than 150%, and when lesion 
diameters are compared to a proximal segment of the same aorta, rather than saline-infused 
controls. The incidence of dissecting AAA is significantly higher when the aneurysm diameter 
is measured at the luminal border (i.e. in vivo) than when external diameters are measured. 
Also, a significantly higher incidence was found when comparing the dissecting AAA segment 
to baseline suprarenal diameters (prior to angiotensin II infusion), and when comparing it to a 
distal segment. Mortality rates showed to be much less dependent on the measurement related 
factors.  
Stratification for measurement related factors 
A Fisher’s exact test indicated that study design significantly correlated with the reference to 
which the suprarenal diameter was compared and also with the percentage increase in diameter 
that was used as a threshold to define the presence of dissecting AAA (Table 3). More 
specifically, researchers tend to use less stringent criteria for diameter increase in studies 
designed to reduce dissecting AAA (Figure 2). Also, researchers conducting treatment studies 
(be it to enhance or to reduce dissecting AAA) more often measure the outer diameter (rather 
than the lumen) and compare suprarenal diameter values more often to those of saline-infused 
mice than researchers in descriptive studies. The difference is most outspoken in studies 
designed to reduce dissecting AAA (Figure 2).  
For studies designed to enhance dissecting AAA, additional stratification for measurement 
related factors removes the difference in incidence with studies designed to describe dissecting 
AAA (Table 4, Figure 5, top). This is the case when withholding only those studies in which 
the suprarenal diameter is compared to the diameter of saline-infused mice, but also when 
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withholding only studies in which a diameter criterion of 150% was used, and when 
withholding only studies in which the external diameter was measured (rather than the luminal 
diameter). Conversely, for studies designed to reduce dissecting AAA this stratification led to 
a further increase in the odds ratio for both the saline reference and the external diameter. For 
these studies the difference in incidence only became (borderline) insignificant when only those 
studies in which a diameter criterion of 150% was used were selected. In order to account for 
the low amount of mice remaining after such stringent stratification, we subsequently visualized 
the effect of stratification for all values of each measurement factor, ignoring any effect of 
environmental confounding factors. For studies designed to reduce dissecting AAA, the odds 
ratio only decreased for studies that compared dissecting AAA diameters to a baseline 
reference, for those using a threshold < 150%, or for those measuring the luminal diameter 
(Figure 5, bottom). 
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Discussion 
The last years a plethora of studies have used angiotensin II-infused mice to study dissecting 
AAA in mice: 93 of the 194 studies analyzed in this meta-analysis were published between 
2012 and 2015. In the first part of this meta-analysis we provide the research community with 
reference values concerning the incidence and mortality rates of dissecting AAA in this mouse 
model, and report to what extent these values are influenced by environmental confounding 
factors such as sex, age, diet, genetic background and angiotensin II dose. In the second part 
we focus on the apparent discrepancy in reported incidence rates for studies designed to 
enhance and studies designed to reduce dissecting AAA. We investigate possible causes for 
this potential bias, and propose alternative criteria for dissecting AAA detection in future 
research. 
Dissecting AAA incidence and mortality and their confounding factors 
Our meta-analysis is the first to come up with incidence, severity and mortality rates that are 
representative for a large sample of mice. We found an overall incidence rate of 60% and a 
mortality rate of 20%. While both incidence rates and mortality rates vary significantly in 
between labs (as evidenced by the high standard deviations when calculating dissecting AAA 
incidence on a study level, Table 1), we think that these numbers, along with the confounding 
factor-dependent incidence rates provided in Table 2, can provide an important reference for 
future researchers planning to use this mouse model. The incidence rates of Grade I-Grade IV 
morphology should be interpreted with caution as these categories have not been defined very 
strictly. When first introducing the subdivision into Grade I – Grade IV, Daugherty et al. 
already stated to have “arbitrarily defined aneurysms based largely on the visual characteristics” 
20
. Especially the Grade IV category is to be interpreted with caution, as some authors 
automatically include mice succumbing to aneurysm rupture as Grade IV, while others do not. 
Nevertheless, we believe that our data are the first to gather representative statistics on the 
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distribution of these morphological features of murine dissecting AAA, and can as such be 
important for the interpretation of future results. 
When it comes to confounding factors influencing dissecting AAA, we found that incidence 
and mortality in angiotensin II-infused mice are much higher in male than in female mice. This 
result confirms earlier findings 37, and is also in correspondence with what is observed in human 
aneurysms 1, 38. Our analysis also confirms earlier reports that C57Bl\6 mice have lower 
dissecting AAA incidence and mortality than ApoE-/- mice, while C57Bl\6 that are injected 
with anti-TGF-β have a significantly higher dissecting AAA incidence and mortality 39. The 
reason behind these observations is the subject of ongoing discussion 40, 41. 
We further demonstrate that, while a lower dose reduces incidence and mortality of dissecting 
AAAs, increasing the dose of angiotensin II plays a less important role in incidence than what 
is commonly assumed 42. Even when the threshold was fixed at very high levels (> 2000 
ng/kg/min), a high dose of angiotensin II did not significantly increase dissecting AAA 
incidence nor mortality. This is important information that may be used when planning future 
experiments.  
Age turned out not to be related to the incidence of dissecting AAA to the same extent as sex, 
background and dose. While incidence was significantly different for young and old mice, 
mortality was not. Moreover, the odds ratio for dissecting AAA incidence was less outspoken, 
and the confidence interval closer to 1, than for other confounding factors. The thresholds to 
define young (< 9 weeks) and old (> 24 weeks) mice were based on biological evidence43, 
allowing for a reasonable distribution between categories (Figure 2). However, if the age limits 
were put at 10 weeks and 20 weeks, neither young nor old mice showed a significant difference 
in dissecting AAA incidence (or mortality). This indicates that the dependency of dissecting 
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AAA incidence on age is less robust than its dependency on, for instance, sex or angiotensin II 
dose.   
Surprisingly, only moderate and non-significant effects were noted for mice on a high-fat diet. 
The reason might be that we treated high-fat diet as a binary variable and did not include the 
amount of cholesterol into the analysis. Most likely a significant difference would have been 
obtained if a dose-dependent analysis (such as for age and angiotensin II dose) had been 
performed. The results of the analysis regarding high-fat diet should therefore be interpreted 
with caution.  
The enhancement of reductions and the reduction of enhancements: a short analysis 
The most surprising result of our analysis was the strong dependence on study design that was 
found in both incidence and mortality of dissecting AAA in non-treated, angiotensin II-infused 
mice that were used as control animals in treatment studies. In part, this can be explained by an 
intentional selection bias, as researchers select animals with a low incidence (e.g. low dose, 
wild type mice) when the aim of their study is to enhance dissecting AAA, and focus on animals 
at higher risk (e.g. male mice or high doses of angiotensin II) when the aim of the study is to 
reduce dissecting AAA (Figure 2). Nevertheless, a stratified analysis demonstrated that the 
design-dependency of aneurysm incidence was independent of genetic background, sex or dose 
of angiotensin II. On the other hand, the design-dependency of mortality was found to 
normalize after stratification (Figure 3). But while mortality is a binary variable that, in 
principle, cannot be interpreted wrongly, dissecting AAA incidence is a measurement that is 
prone to interpretation.  
We therefore hypothesized that a possible explanation for the dependency of dissecting AAA 
incidence on study design could be found in a detection bias with respect to the definition (and 
the interpretation of that definition) that was used to quantify dissecting AAA presence. Indeed, 
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a thorough analysis revealed the existence of no less than 30 possibilities to quantify the 
dilatation related to aneurismal widening of the suprarenal segment of the aorta. On top of this, 
16% of the studies did not quantify anything at all, as they simply defined dissecting AAA 
presence after visual inspection of the post mortem tissues. Figure 4 confirms that, while the 
incidence of dissecting AAA is significantly different for several measurement related factors, 
mortality is not. The additional stratification in Figure 5 suggests that the dependency of 
dissecting AAA incidence on study design was to a great extent determined by the measurement 
method that was used. These data are further supported by the results of the Fisher exact test 
(Table 3), which demonstrate that both the reference to which diameters are compared and the 
threshold in percentage increase used to define dissecting AAA are significantly correlated with 
study design. The results of these stratified analyses should be interpreted with caution due to 
the relatively low number of animals remaining after stratification for measurement-related 
factors. Nevertheless, this hypothesis is worrying, as it suggests that dissecting AAA incidence 
may depend on the method that was used to quantify it.   
Another possible explanation for the dependency of incidence and mortality on study design is 
publication bias. If the control group in an experiment designed to reduce dissecting AAA has 
a high incidence of dissecting AAA, then the treatment group is more likely to significantly 
reduce that incidence. Conversely, when the control group reveals an average incidence, then 
it is more likely that the incidence in the treatment group will not be significantly lower. Vice 
versa, if the control group in an experiment designed to enhance dissecting AAA has a low 
incidence, the treatment is more likely to be effective. Since negative results are more difficult 
to publish, many of these studies will never be submitted or accepted in academic journals, and 
will thus not be accounted for in the meta-analysis. Such publication bias might be the reason 
why the incidence and mortality rates of dissecting AAA in our meta-analysis were significantly 
different for treatment and descriptive studies. While hard to verify, this hypothesis is equally 
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worrying as it suggests that many of the statistically significant results in published treatment 
studies were, in fact, chance findings.  
A third hypothesis is that the dissecting AAA incidence and mortality rates suffered from a 
systematic bias between treatment and control groups that was related to the design of the 
studies but was not included in the stratification. As discussed in depth by Krauth et al. 44, 
additional sources of bias in animal studies (other than the ones already mentioned above) 
include attrition bias (i.e. not accounting for all animals included in the study), non-randomized 
treatment allocation, non-blinded analysis, the use of animals with comorbidity, non-
compliance with animal welfare requirements, the use of inappropriate statistical models, an 
incorrect sample size calculation or financial conflicts of interest. We have not stratified for 
these potential sources of errors as (i) unlike for selection bias, detection bias or publication 
bias, there was no clear hypothesis to link these factors to study design, and (ii) each additional 
stratification step would reduce the number of remaining animals, and hence further increase 
the size of the confidence intervals. Nevertheless, it is important to take these potential sources 
of error into account when planning future experiments. 
Possible solutions and suggestions for future research 
When interpreting the results of pre-clinical studies investigating the effect of pharmacological 
or genetic treatment on dissecting AAA incidence, one often implicitly assumes that the latter 
is an unequivocal, straightforward observation that is not susceptible to interpretation. Reality, 
however, is different. In a clinical setting, a luminal increase of 150 % in aortic diameter is 
typically used as the cut-off criterion to define AAA incidence. This is an artificial limit that is 
based on the clinical reality that smaller dilatations are at a lower risk of rupture and should 
therefore not be treated since the surgery risk would outweigh the rupture risk 45. Despite the 
fact that treatment studies in a pre-clinical research setting function within an entirely different 
paradigm, the definition of dissecting AAA has not been adjusted accordingly. Already in 2007, 
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Jiang et al. argued that the “pseudoaneurysms” induced by angiotensin II are a binary event, 
and that measures of the luminal or external aortic diameter might not accurately reflect the 
development of murine dissecting AAA, especially when studying the effect of drugs on 
dissecting AAA incidence and severity 46. Here, we suggest two different strategies for both the 
quantification and interpretation of dissecting AAA incidence in studies using the angiotensin 
II-infused ApoE-/- mouse model: 
(i) When analyzing data, future researchers should refrain from reporting either 
external or luminal diameters as if they were a single and non-biased expression of 
dissecting AAA incidence. Instead, the effect of treatment studies should be 
quantified on a micro-structural level, quantifying e.g. the elastin and collagen 
content, the size of the intramural thrombus, or the number of branches affected. 
(ii) When interpreting data, future researchers should keep the possibility of publication 
bias into account, and compare incidence and mortality rates of the angiotensin II-
infused control group to the reference values provided in this meta-analysis. 
Limitations 
The data extraction for the meta-analysis has been performed by a single operator (B.T.). We 
chose to maximize the number of animals by including those manuscripts in which aneurysm 
incidence or mortality rates were not mentioned in written text, but only in the form of bar plots, 
or relative to the group size. Therefore some of the values on dissecting AAA incidence and 
mortality mentioned in table S1 may be prone to interpretation errors, while others may have 
gone undetected while they were mentioned within the manuscript. Given the sample size that 
was achieved, such errors are expected to be randomly distributed and should not affect the 
conclusions of our work. We would like to point out that the number of studies reporting 
incidence values was in general greater than those reporting mortality values. In order not to 
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lose a significant amount of data prior to stratification, the latter was performed for the largest 
possible groups in both cases. A more stringent interpretation, only taking into account those 
studies that reported both incidence and mortality, resulted in larger confidence intervals, but 
did not change the interpretation of the results for dissecting AAA incidence. We did not report 
these results as the odds ratios for mortality became more difficult to interpret, due to the low 
number of studies remaining after stratification. On a similar note, the wide confidence intervals 
after stratification for the measurement methods indicate that the number of mice remaining in 
this cohort after many subsequent stratification steps was quite low (Figure 5, Table 4). While 
the exact numerical values of this part of the stratification should therefore be interpreted with 
caution, they do not alter the main conclusions, which are supported by the Fisher exact test 
that was carried out on a study level (Table 3).  
Conclusions  
We have performed a meta-analysis to provide overall as well as stratified, confounding factor-
dependent incidence, severity and mortality rates for dissecting AAA in angiotensin II-infused 
mice. We strongly believe that these numbers have the potential to serve as reference data and 
will allow for a more accurate study design when planning experiments using the angiotensin 
II-infused mouse model. The reported incidence and mortality rates were higher for angiotensin 
II-infused mice that served as control animals in studies designed to reduce dissecting AAA, 
and lower for mice that served as control animals in studies designed to enhance dissecting 
AAA. Stratification showed that this dependency could be explained by an intentional selection 
bias of environmental confounding factors (sex, dose, genetic background, age, diet) for 
dissecting AAA mortality, but not for dissecting AAA incidence. We subsequently 
hypothesized that the dependency of dissecting AAA incidence on study design may be related 
to the variability in methods used to quantify dissecting AAA, and that literature may be 
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distorted by a publication bias. We conclude that, before any further treatment studies are 
performed, the translational aspects of this mouse model should be further documented and the 
relevance of diameter increase as a single quantification of dissecting AAA incidence should 
be questioned.  
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Figures 
Figure 1. Odds ratios and 95% confidence intervals for environmental confounding factors. 
Every factor is compared to its reference value (male sex, ApoE -/- background, age 9-24 weeks, 
normal diet, dose 750 - 1250 ng/kg/min , long infusion time, study designed to describe 
dissecting AAA). Odds ratios are considered significant if the confidence interval does not 
contain the value 1. Factors are shown in order of increasing p-value. 
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Figure 2. Histograms indicating the prevalence of each category for both environmental 
confounding factors (top 6 panels) and measurement-related factors (bottom 3 panels) on a 
study level. Histograms are subdivided for 3 different study designs and normalized by the 
number of studies, which can be found in Table 3.   
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Figure 3. Step-wise stratification to investigate whether environmental confounding factors can 
explain the dependency of dissecting AAA incidence and mortality on study design. Factors 
were included in decreasing order of significance of their correlation with study design, as 
determined from Fisher’s exact test on a study level (see Table 3). Top panels show that 
dissecting AAA incidence remains significantly different after stratification, while bottom 
panels show that dissecting AAA mortality becomes independent of study design after 
stratification.  
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Figure 4. Odds ratios and 95% confidence intervals for measurement related factors. Every 
factor is compared to its reference value (a 150% increase in dissecting AAA external diameter, 
with a reference diameter obtained from the same supra-renal segment in saline-infused mice). 
Odds ratios are considered significant if the confidence interval does not contain the value 1. 
  
32 
 
Figure 5. Step-wise stratification to investigate whether measurement-related confounding 
factors can explain the dependency of dissecting AAA incidence and mortality on study design. 
Top. The starting point are reference mice with additional stratification for factors significantly 
correlated with study design (sex, background, dose) and infusion time. The reference values 
of each measurement related factor (saline reference, 150% increase, external measurement) 
were included in decreasing order of significance of their correlation with study design, as 
determined from Fisher’s exact test on a study level (see Table 3). The effect of including age 
and diet was investigated for each factor as well. Bottom. The starting point are all mice, 
without any prior stratification.  The influence of stratification is subsequently shown for all 
values of each measurement method.  
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Tables  
  N  N  N mice Incid. (%) Incid. (%) Std. (%) 
  studies mice Total mice studies studies 
Incidence 187 1977 3320 60 59 31 
Mortality 129 573 2865 20 18 19 
Grade I 33 93 429 22 28 28 
Grade II  33 110 429 26 26 24 
Grade III  33 125 429 29 27 22 
Grade IV 33 101 429 24 18 20 
 
Table 1.  Dissecting AAA incidence, severity and mortality for all studies included in the meta-
analysis. Incidence values were obtained both on an individual mouse level (Incid. mice), taking 
into account the amount of mice in each study, or on a study level (Incid. studies), averaging 
incidence values of all studies, irrespective of the amount of mice in each study. Std: standard 
deviation.  
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Table 2.  Odds ratios and 95% confidence intervals for incidence rates (left) and mortality rates 
(right) of dissecting AAA in association with environmental confounding factors (top) and 
measurement-related factors (bottom). Every factor is compared to its reference value (male 
sex, ApoE -/- background, age 9-24 weeks, normal diet, dose 750-1250 ng/kg/min, infusion time 
> 6 days, study designed to describe dissecting AAA, diameter measured externally, dissecting 
AAA defined as a diameter increase  of  150%, in comparison with saline-infused reference 
animals). Odds ratios are considered significant if the 95% confidence interval does not contain 
the value 1. Factors are listed in order of increasing p-value for the odds ratio of dissecting 
AAA incidence. 
  
Incid.: Incidence, Mort.: Mortality, OR: Odds Ratio, CI: Confidence Interval, ref: reference, 
NsI: number of studies reporting incidence, NsM: number of studies reporting mortality. 
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  NsR NsD NsE p-value p-value p-value 
Environmental factors       Fs 
Fm 
incid. 
Fm 
mort. 
Sex 120 61 52 2.2E-05 8.3E-54 7.7E-07 
Background 120 62 44 8.2E-04 N\A 1.9E-26 
Ang II dose 126 68 55 1.7E-03 2.0E-72 6.5E-23 
Infusion time 127 68 55 1.2E-01 1.7E-06 1.0E+00 
Age 123 63 43 3.6E-01 2.2E-10 2.0E-05 
Diet 127 68 55 9.6E-01 1.3E-05 3.2E-02 
Measurement factors             
Reference diameter 31 58 24 2.7E-03 N\A 3.7E-29 
Threshold increase 78 32 37 2.4E-02 2.7E-36 1.2E-35 
Diameter location 65 32 29 1.3E-01 7.3E-22 4.2E-14 
 
Table 3.  Results of Fisher’s exact test indicate to what extent each confounding factor is related 
to study design. Fisher’s exact test was computed both on a study level (Fs) and for dissecting 
AAA incidence and mortality on an individual mouse level (Fm). Corresponding histograms 
on a study level are shown in Figure 2, and the corresponding p-values determined the order of 
stratification in Figures 3 and 5. 
NsR: number of studies designed to reduce dissecting AAA, which report the indicated factor. 
NsD: number of studies designed to describe dissecting AAA, which report the indicated factor. 
NsE: number of studies designed to enhance dissecting AAA, which report the indicated factor. 
Fs: Fisher’s exact test on a study level. Fm: Fisher’s exact test on an individual mouse level. 
Incid.: incidence. Mort.: Mortality. N\A: not available. Since these factors take 5 different 
values, 3 of which are very infrequent, the Fisher’s exact test could not be computed on an 
individual mouse level. 
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Table 4.  Stratification for environmental confounding factors and measurement-related 
factors. Factors were included in decreasing order of significance of their correlation with study 
design, as determined from Fisher’s exact test (see Table 3). The ‘stratified’ case refers to long 
infusion + normal dose + ApoE-/-  +  male mice. Odds ratios are considered significant if the 
confidence interval does not contain the value 1.  
NsD: number of studies designed to describe dissecting AAA, NsR: number of studies designed 
to reduce dissecting AAA, NsE: number of studies designed to enhance dissecting AAA. 
